Follow
Technology Evaluation
Technology Evaluation encompasses the principles, methods, and techniques needed to get the highest potential value from a particular technology. As part of a Technology Evaluation, an entity, such as a company, working group, region, or industry, asses the contribution of technology to their operations.
FEB 06, 2014 | 7:00 AM
Regulations and guidelines governing the use of animals in research require minimization of pain and distress. However, pharmacologic treatments to prevent or alleviate pain can interfere wit...
FEB 06, 2014 | 6:00 AM
The utility of dried blood spot (DBS) sampling technology for rodent colony health monitoring was investigated using a two-tiered approach. In the first approach, groups of mice and rats were...
NOV 20, 2013 | 8:00 AM
As the scientific evidence base for pharmacogenetics continues to expand, the use of such information in clinical management and drug development will be in demand.
The FDA advises that the...
OCT 17, 2013 | 12:00 PM
C.E. CREDITS
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
OCT 16, 2013 | 12:00 PM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
AUG 22, 2013 | 3:00 PM
C.E. CREDITS
The use of ultrahigh throughput diagnostic tests that determine genetic sequence variation to guide patient care is rapidly expanding, fueled by the enormous growth in sequencing platform dev...
AUG 22, 2013 | 1:00 PM
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
AUG 22, 2013 | 12:00 PM
C.E. CREDITS
It is widely accepted that approximately 85% of known disease-causing DNA variants affect the exons and splice junctions, which is about 1% of the whole genome. As a result, Clinical Exome Se...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
NOV 20, 2013 | 8:00 AM
As the scientific evidence base for pharmacogenetics continues to expand, the use of such information in clinical management and drug development will be in demand.
The FDA advises that the...
OCT 17, 2013 | 12:00 PM
C.E. CREDITS
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
OCT 16, 2013 | 12:00 PM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
OCT 16, 2013 | 11:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
OCT 16, 2013 | 6:00 AM
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
AUG 22, 2013 | 3:00 PM
C.E. CREDITS
The use of ultrahigh throughput diagnostic tests that determine genetic sequence variation to guide patient care is rapidly expanding, fueled by the enormous growth in sequencing platform dev...
AUG 22, 2013 | 1:00 PM
Personalized medicine is transforming biomedical research and healthcare service delivery. Disease definition, diagnosis, treatment, and prevention are being fundamentally altered by the capa...
AUG 22, 2013 | 12:00 PM
C.E. CREDITS
It is widely accepted that approximately 85% of known disease-causing DNA variants affect the exons and splice junctions, which is about 1% of the whole genome. As a result, Clinical Exome Se...
MAY 30, 2013 | 9:00 AM
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...